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Abstract We have found earlier that changes in membrane
cholesterol content have distinct impact on signaling via the
M1, M2, or M3 receptors expressed in CHO cells (CHO-M1
through CHO-M3). Now we investigated whether gradual
changes inmembrane cholesterol exerts differential effects on
coupling of the M1 and M3 muscarinic receptors to prefer-
ential signaling pathways through Gq/11 and non-preferential
Gs G-proteins signaling. Changes in membrane cholesterol
resulted in onlymarginal alterations of antagonist and agonist
affinity of the M1 and M3 receptors, and did not influence
precoupling of either subtype. Changes in membrane cho-
lesterol did not influence parameters of carbachol-stimulated
GTP-c35S binding inCHO-M1membraneswhile reduction as
well as augmentation of membrane cholesterol lowered the
efficacy but increased the potency of carbachol in CHO-M3
membranes. Gradual increase or decrease in membrane cho-
lesterol concentration dependently attenuated agonist-
induced inositolphosphates release while only cholesterol
depletion increased basal values in both cell lines. Similarly,
membrane cholesterol manipulation modified basal and ago-
nist-stimulated cAMPsynthesis viaGs in the sameway inboth
cell lines. These results demonstrate that changes in mem-
brane cholesterol concentration differentially impact prefer-
ential and non-preferential M1 and M3 receptor signaling.
They point to the activated G-protein/effector protein inter-
action as the main site of action in alterations of M1 receptor-
mediated stimulation of second messenger pathways. On the
other hand, modifications in agonist-stimulated GTP-c35S
binding in CHO-M3 membranes indicate that in this case
changes in ligand-activated receptor/G-protein interaction
may also play a role.
Keywords Muscarinic receptors  Agonist binding 
Cholesterol  G-Proteins  Signal transduction  cAMP
synthesis
Introduction
Muscarinic receptors belong to the family of G-protein
coupled receptors (GPCR) that are the most abundant and
pharmacologically targeted plasma membrane receptors [9,
22]. A common structural feature of GPCR is the extracel-
lular N-terminus, seven membrane spanning domains, three
extracellular, three intracellular loops, and intracellular
C-terminus. Stimulation of GPCR leads to activation of
specific G-proteins and their intracellular signaling pathways
that play important regulatory roles in virtually all physio-
logical functions. There are five subtypes of muscarinic
receptors denoted as M1-M5 and encoded by five different
genes [2–5, 31]. Individual muscarinic receptor subtypes
share a high degree of homology in the transmembrane
domains while the extracellular and intracellular loops are
less conserved [13–15]. The intracellular C-terminus may
form the fourth intracellular loop by means of a glycosyl
anchor. The N-terminal part of the third intracellular loop
represents the contact domain for interaction with G-proteins
[12, 37]. Higher variability of this domain enables selectivity
of interaction with different G-proteins.
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The M1, M3, and M5 receptor subtypes preferentially
activate Gq/11 G-protein intracellular signaling while the
M2 and M4 subtypes prefer Gi/o G-proteins and activate
their signaling pathways [20, 21]. However, it has been
demonstrated that individual subtypes of muscarinic recep-
tors can also interact with and activate non-preferential
G-proteins [17, 19, 26, 27]. We have previously reported
that experimental changes in membrane cholesterol con-
centration have various impacts on preferential second
messenger signaling mediated by M1, M2, and M3 musca-
rinic receptors [28]. With respect to M1 and M3 receptors
that prefer Gq/11 G-proteins we found that both increase and
decrease in membrane cholesterol attenuates maximal effect
(efficacy) of carbachol, a non-hydrolysable analog of the
natural agonist acetylcholine, in stimulating inositolphos-
phates (IPs) accumulation but does not influence its potency.
In contrast, an increase in membrane cholesterol had no
influence on preferential M2 receptor mediated inhibition of
cAMP synthesis while cholesterol depletion increased inhi-
bition by carbachol without influencing its potency.
However, as mentioned above, odd numbered muscarinic
receptors expressed in CHO cells also activate Gs G-pro-
teins. There can be mechanistic differences between Gq/11
and Gs G-protein activation of intracellular signaling path-
ways mediated by M1 or M3 receptors. While these recep-
tors expressed in CHO cells precouple with Gq/11 and Gi/o
G-proteins they do not precouple with Gs G-proteins [19]. In
the present experiments we explored the influence of gradual
changes in membrane cholesterol concentration on individ-
ual steps of signal transduction via M1 muscarinic receptors,
including agonist binding, activation of G-proteins, and
resulting stimulation of intracellular signaling pathways. Our
aim was to reveal if there are differences between the effects
of changing membrane cholesterol content on Gq/11 and Gs
G-proteins signaling. To achieve this goal we determined
binding parameters and functional response in CHO cells
expressing the muscarinic M1 receptor (CHO-M1 cells) that
prevails in the brain. For comparison we used CHO cells
that express the M3 muscarinic receptor (CHO-M3). We
demonstrate that changes in membrane cholesterol do not
influence precoupling of either M1 or M3 receptors and
result in only marginal alterations of antagonist and agonist
affinity. Despite only slight alterations of receptor/G-protein
interactions both increase and decrease in membrane cho-
lesterol evoked significant modifications in cAMP synthesis.
Methods
Cell Lines, Treatments, and Chemicals
Experiments were performed essentially as described pre-
viously in Michal et al., 2009 [28]. Briefly, CHO cells
stably transfected with the human genes of the muscarinic
M1 and M3 receptor subtypes (CHO-M1 and CHO-M3
cells, respectively) were kindly supplied by Prof. Tom
Bonner. Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) with 10 % fetal calf serum and 0.005 %
geneticin, and used for experiments three to 5 days after
seeding. Cells were grown in 10 cm diameter Petri dishes
for preparation of membranes or in 24-well or 48-well
plates for assays on intact cells. Before experiment, cells
for functional assays were loaded with 3H-adenine for 4 h
or with 3H-myo-inositol for 4–12 h in DMEM. Then they
were treated for 1 h at 37 C in DMEM with indicated
concentrations of methyl-b-cyclodextrin (MBCD; ranging
from 1.25 to 10 mM) to deplete membrane cholesterol or
with cholesterol-saturated methyl-b-cyclodextrin (Ch-
MBCD; ranging from 0.25 to 4 mM) to increase membrane
cholesterol. Cholesterol-modifying medium was washed
off using DMEM and cells were used for measurements on
intact attached cells or for preparation of membranes for
binding assays.
Chemicals were obtained from Sigma (Prague, Czech
Republic) unless indicated otherwise.
Membrane Preparation
Membranes were prepared as described by Jakubı´k et al.
[17] from control cells or from cells that had been treated
with cholesterol-modifying agents as described above.
Saturation and Competition Binding Assays
Binding characteristics of muscarinic receptors were
determined in equilibrium binding experiments with the
membrane-impermeable quaternary amine muscarinic
antagonist [3H]-N-methylscopolamine (3H-NMS) (ARC,
USA) as a tracer. Densities and affinities of muscarinic
receptors were determined in saturation assays on intact
attached cells or cell membranes as described [17, 18, 33].
Intact cells were incubated for 1 h at 37 C in 0.5 ml of
DMEM containing increasing concentrations of 3H-NMS
ranging from 63 pM to 2.0 nM. Attached cells were then
quickly washed with cold phosphate buffered saline to
remove unbound ligand, dissolved in 1 M NaOH, and
aliquots of these lysates were used for scintillation count-
ing and protein determination. Membranes were suspended
in binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM
Na-HEPES, pH 7.4) and aliquots (5–20 lg of protein in a
final volume 400 ll) in 96-well-plate were incubated for
1 h at 25 C in the presence of 63 pM–2 nM 3H-NMS.
Incubation was terminated by filtration through Whatman
GF/B glass fiber filters (Whatman) using a Brandel har-
vestor (Brandel, USA). Filters were dried and counted in
scintillation cocktail Rotiszint (Carl Roth, Germany) in
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Wallac Microbeta scintillation counter (Wallac, Finland).
Non-specific binding was determined in the presence of
10 lM atropine.
Binding characteristics of the muscarinic agonist car-
bachol were determined analogically in competition
experiments with 1 nM [3H]-NMS as a tracer.
Functional Assays
IPs accumulation and cAMP production were assayed in
attached cells grown in 24-well-plates as described [28].
For cAMP synthesis measurements, [3H]-adenine (10 lCi/
ml; GE Healthcare, UK) labeled control or treated cells
were preincubated in DMEM containing 1 mM isobu-
tylmethylxanthine for 15 min and then in the presence of
increasing concentrations of carbachol for 10 min at 37 C.
The reaction was stopped by adding trichloroacetic acid
(TCA) and cyclic [14C]-AMP (GE Healthcare, UK) that
was used as recovery standard. Aliquots of TCA extracts
were used for determination of TCA-soluble radioactivity
and separation of [3H]-AMP from other labeled metabolites
[16, 27]. TCA precipitates were dissolved in 1 M NaOH
and used for determination of protein content.
For IPs accumulation, [3H]myo-inositol (10 lCi/ml; GE
Healthcare, UK) labeled control or treated cells were pre-
incubated in DMEM containing 12 mM LiCl for 15 min
and then in the presence of increasing concentrations of
carbachol for 10 min at 37 C. The incubation was stopped
on ice by adding TCA. Accumulated TCA-soluble radio-
activity was used for estimation of formation of inositol
phosphates without further separation [28]. TCA precipi-
tates were dissolved in 1 M NaOH and aliquots of these
lysates were used for scintillation counting for determina-
tion of radioactivity loading and protein content
determination.
Activation of G-proteins by agonist reflects signal
transduction across plasma membrane. Muscarinic recep-
tor-induced activation of G-proteins was determined as an
increase of GTP-c35S binding to membranes induced by
the muscarinic receptor agonist carbachol as described [17,
24]. Aliquots of membranes containing 5–20 lg protein
were preincubated in 96-well-plate at 30 C in binding
buffer containing in addition 1 mM DTT, 1 lM GDP, and
concentrations of carbachol ranging from 0 to 100 lM.
Reaction was started by adding GTP-c35S (Biotrend
Chemikalien, Germany; SRA 1,000 Ci/mmol) to give a
final concentration of 500 pM and incubation continued for
another 20 min. Total content of G-proteins in membranes
was determined as GTP-c35S binding in the absence of
GDP. Nonspecific binding was assessed in the presence of
10 lM unlabeled GTP. Incubation was terminated by rapid
vacuum filtration through Whatman GF/F filters using
Tomtec Harvester Mach III (USA). Radioactivity retained
on filters was determined using solid scintillator Meltilex
(Perkin Elmer, USA) as described for [3H]-NMS binding to
membranes.
Data Evaluation
Curve fitting and statistical evaluation of data was done
using Prism 6 (GraphPad Software Inc., CA, USA). Rect-
angular hyperbola was fitted to data obtained in saturation
analysis experiments. A sigmoidal concentration–response
curve equation with constant or variable slope as appro-
priate was fitted to data obtained in GTP-c35S binding and
cAMP synthesis experiments. A two-sites displacement
curve equation was fitted to data obtained in displacement
experiments. Better fits were determined using F test. The
significance of differences among groups was tested by
Anova and indicated post hoc test or t test as appropriate.
Results are shown as mean ± SEM.
Results
We did not find differences between CHO-M1 and CHO-
M3 cells in cell or membrane cholesterol concentration,
either in control values or values after treatment with
MBCD or Ch-MBCD. These values were therefore pooled
(Table 1). Changes in cell and membrane cholesterol
concentration were proportional.
Treatment of CHO-M1 and CHO-M3 cells with 10, 7.5,
5, 2.5 or 1.25 mM MBCD or with 0.25, 0.5, 1, 2 or 4 mM
Ch-MBCD resulted in expected concentration-dependent
changes in membrane cholesterol concentration (see legend
to Fig. 1). Changes in membrane cholesterol content
(control cells 225 nmol/mg protein) ranged from a
decrease induced by 10 mM MBCD to 62 nmol/mg protein
up to an increase to 768 nmol/mg protein induced by
4 mM Ch-MBCD. The decrease as well as the increase in
membrane cholesterol content concentration-dependently
attenuated the efficacy of carbachol in stimulating IPs
accumulation in both CHO-M1 and CHO-M3 cells
(Fig. 1a). In contrast, decreasing membrane cholesterol
concentration dependently increased resting IPs accumu-
lation in both cell lines while an increase in membrane
cholesterol had no effect (Fig. 1b). Nevertheless, CHO-M1
cells were somehow more sensitive to changes in mem-
brane cholesterol concentration with respect to both resting
and carbachol-evoked accumulation of IPs.
A decrease in membrane cholesterol augmented (by 139
and 59 % for M1 and M3 receptors, respectively; p\ 0.01
for both subtypes) while an increase in membrane choles-
terol lowered (to 66 and 56 % for M1 and M3 receptors,
respectively; p\ 0.01 for both subtypes) binding of the
muscarinic receptor antagonist 3H-NMS in both cell lines.
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Data are expressed as mean ± SEM of n experiments (in parentheses). Values for cholesterol concentrations were pooled because they did not
differ between CHO-M1 and CHO-M3 cells and membranes. * p\ 0.05; ** p\ 0.01; significantly different from controls (middle column) by
Anova followed by Dunnett’s multiple comparison test
(a) (b)
Fig. 1 Influence of membrane cholesterol concentration on efficacy of
signal transduction in CHO-M1 and CHO-M3 cells. IPs accumulation
in intact CHO cells expressing M1 (open squares) or M3 (closed
squares) receptors induced by 100 lM carbachol was determined in
cells pretreated with various concentrations of MBCD or cholesterol-
saturatedMBCD to decrease or increasemembrane cholesterol content,
respectively. Accumulation of IPs in the presence (a) or absence (b) of
carbachol, expressed in percent of incorporated radioactivity (ordinate),
is plotted against membrane cholesterol concentration (abscissa)
determined after treatments. The cells were treated with 10–7.5–5–
2.5–1.25 mM MBCD to reduce membrane cholesterol or with
0.25–0.5–1–2–4 mM Ch-MBCD to increase membrane cholesterol as
described in ‘‘Methods’’ section. The corresponding averaged values of
membrane cholesterolwere 62, 82, 103, 146, 188, control 225, 251, 297,
344, 607, and 768 nmol/mg protein. Points are mean ± SEM of 3–4
experiments in triplicates. No treatment, control cells. **, p\ 0.01
significantly different from control cells (dotted line) by Anova
followed by Dunnett’s multiple comparison test
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The affinity of 3H-NMS binding was only marginally
affected by membrane cholesterol manipulation but, sur-
prisingly, differed between receptor subtypes. Maximal
cholesterol depletion decreased the affinity of 3H-NMS
binding in CHO-M1 cells (from 259 to 455 pM; p\ 0.05)
but had no effect in CHO-M3 cells. Conversely, maximal
supplementation of cholesterol decreased the affinity of
3H-NMS binding in CHO-M3 cells (from 245 to 397 pM;
p\ 0.01) but had no effect in CHO-M1 cells.
Changes in membrane concentration of cholesterol in
CHO-M1 cells also had only marginal effects on agonist
binding. In competition experiments summarized in
Table 2 we used carbachol that is a non-hydrolysable
analog of natural agonist acetylcholine and 3H-NMS as a
tracer. Maximal cholesterol depletion induced by 10 mM
MBCD significantly decreased the affinity of agonist low
affinity binding in CHO-M1 cells (from 168 to 330 lM;
p\ 0.01) but had no effect on the proportion or affinity of
high affinity binding sites. In contrast, it has no effect on
the binding parameters of carbachol in CHO-M3 cells as
well as in CHO-M1 and CHO-M3 membranes. Similarly,
membrane cholesterol supplementation had no effect on
the parameters of carbachol binding in either CHO-M1 or
CHO-M3 cells or analogous membranes.
In the next two sets of experiments we probed the effects of
changing membrane cholesterol content in functional tests
characteristics of signal transduction across cell membrane
and activation of the intracellular signaling pathways medi-
ated by Gs G-proteins. First we tested carbachol-evoked
stimulationofGTP-c35Sbinding inmembranes (Fig. 2).Total
binding of GTP-c35S (1 h incubation in the absence of GDP)
that represents the level of activity of all available G-proteins
incorporated inmembranes did not differ betweenM1andM3
membranes so the results were pooled (Table 3). Cholesterol
depletion resulted in a small but significant increase of GTP-
c35S binding sites (by about 19 %; p\ 0.01) while choles-
terol supplementation slightly decreased GTP-c35S binding
(by about 8 %; p\ 0.05). Resting binding of GTP-c35S was
significantly reduced in both CHO-M1 and CHO-M3 cho-
lesterol-depleted membranes (by about 32 and 12 %,
respectively; p\ 0.01 for both subtypes) and slightly
increased only in CHO-M1 cholesterol-supplemented mem-
branes (by about 12 %; p\ 0.05). Concentration–response
relationship of carbachol-induced stimulation of GTP-c35S
binding (Fig. 2) in CHO-M1 membranes was best fitted by a
four-parameter equation (with Hill slope)while that for CHO-
M3 membranes by a regular sigmoidal concentration–
response curve (three-parameter equation). Neither choles-
terol depletion nor cholesterol supplementation changed the
shape of the concentration–response curves. Changes in
cholesterol of CHO-M1 membranes did not influence either
maximal response evoked by carbachol (Emax) or concentra-
tion of carbachol inducing half-maximal stimulation (EC50).
In contrast, both elevation and depletion of membrane cho-
lesterol of CHO-M3 membranes significantly increased
potency of carbachol (p\ 0.01) but attenuated maximal
response (Table 3). Changes in parameters of basal and car-
bachol-evoked cAMP synthesis in intact CHO-M1 and CHO-
M3 cells after cholesterol modifying treatments were similar
for both cell lines (Fig. 3, Table 4). Depletion of membrane
cholesterol increased basal and carbachol-evoked cAMP
synthesis (p\ 0.05 for both subtypes) while supplementation
of membrane cholesterol had no effect on basal synthesis of
cAMP but reduced cAMP synthesis evoked by carbachol
(p\ 0.05 for both subtypes). None of the treatments influ-
enced potency of carbachol.
Discussion
The M1 muscarinic receptor is a major cerebral muscarinic
receptor subtype that is essential for cognitive functions.
Any malfunction of its Gq/11 G-protein-mediated signaling
may thus adversely impact not only mental performance but
also amyloid precursor protein processing and amyloid-b
Table 2 Influence of changes in cholesterol concentration on car-






Ki high (lM) 9.3 ± 3.9 5.6 ± 3.6 5.1 ± 3.6
Ki low (lM) 330 ± 34** 168 ± 23 239 ± 38
fH (%) 34.9 ± 5.0 28.4 ± 4.5 25.6 ± 4.9
(n) (7) (7) (7)
M3 cells
Ki high (lM) 4.7 ± 2.1 4.0 ± 3.0 4.1 ± 1.9
Ki low (lM) 87.0 ± 6.4 97.0 ± 17.7 84.8 ± 11.6
fH (%) 24.3 ± 5.5 12.3 ± 2.9 18.7 ± 1.5
(n) (7) (5) (6)
M1 membranes
Ki high (lM) 2.9 ± 1.1 3.3 ± 0.9 2.5 ± 0.2
Ki low (lM) 280 ± 47 233 ± 21 202 ± 21
fH (%) 29.9 ± 2.3 26.9 ± 2.1 28.8 ± 1.9
(n) (5) (6) (5)
M3 membranes
Ki high (lM) 1.42 ± 0.61 1.06 ± 0.56 0.40 ± 0.16
Ki low (lM) 80.4 ± 22.4 86.8 ± 31.3 53.4 ± 14.3
fH (%) 42.9 ± 3.3 45.8 ± 2.4 43.6 ± 2.7
(n) (3) (3) (3)
Data are expressed as mean ± SEM of n independent experiments (in
parentheses) in triplicates. Parameters of carbachol binding were
calculated as described in ‘‘Methods’’. ** p\ 0.01; significantly
different from controls (middle column) by Anova followed by
Dunnett’s multiple comparison test
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generation [6, 29, 30]. We probed the influence of changing
membrane cholesterol concentration on M1 and M3 receptor
activation and signaling. Our results indicate that both an
increase and a decrease in membrane cholesterol con-
centration-dependently attenuate maximal stimulation of
preferential M1 and M3 receptor-mediated Gq/11 G-protein
(a) (b)
Fig. 2 Influence of membrane cholesterol concentration on carba-
chol-evoked GTP-c35S binding in CHO-M1 and CHO-M3 mem-
branes. Membranes were prepared from cells pretreated with various
concentrations of MBCD or cholesterol-saturated MBCD to decrease
or increase membrane cholesterol content, respectively. Increase in
GTP-c35S binding in CHO-M1 (a) and CHO-M3 (b) membranes
expressed in ccpm/lg protein (ccpm, corrected cpm) is plotted against
carbachol concentration (abscissa; log M). The cells were treated with
10 or 5 mM MBCD (closed and opened circles, respectively) to
reduce membrane cholesterol, or with 2 or 4 mM Ch-MBCD (open
diamond and closed diamonds, respectively) to increase membrane
cholesterol as described in ‘‘Methods’’. Points are mean ± SEM of
2–3 experiments in triplicates or quadruplicates. Closed squares,
control (DMEM treated) cells. Parameters of fits (four parameter
sigmoidal equation for CHO-M1 cells and three parameters equation
for CHO-M3 cells) are shown in Table 3
Table 3 Influence of changes




Data are expressed as
mean ± SEM of n experiments
(in parentheses) in triplicates or
quadruplicates. Values for GTP-
c35S binding are expresse in
ccpm/lg protein. Values for
total binding in CHO-M1 and
CHO-M3 membranes did not
differ so they were pooled.
* p\ 0.05; ** p\ 0.01;
significantly different from
controls (middle column) by










Pooled M1 and M3
Total binding
(ccpm/lg)
5,310 ± 82** 4,987 ± 56** 4,469 ± 57 4,410 ± 63 4,127 ± 121*
(n) (6) (4) (6) (4) (6)
M1 membranes
Basal binding 1,004 ± 46** 997 ± 24** 1,473 ± 57 1,643 ± 32* 1,529 ± 30
Emax (ccpm/lg) 854 ± 31 857 ± 39 974 ± 11 810 ± 4 819 ± 81
EC50 (lM) 42.5 ± 4.0 44.4 ± 11.8 64.6 ± 16.8 22.4 ± 0.9 18.5 ± 0.2
Hill slope 0.708 ± 0.052 0.745 ± 0.119 0.720 ± 0.066 0.679 ± 0.009 0.758 ± 0.059
(n) (3) (2) (3) (2) (3)
M3 membranes
Basal binding 1,096 ± 30** 1,172 ± 18 1,248 ± 27 1,333 ± 34 1,278 ± 17
Emax (ccpm/lg) 77.0 ± 11.0** 118.5 ± 0.5** 401 ± 30.8 341.5 ± 43.5 254.7 ± 18.9*
EC50 (lM) 2.7 ± 1.0** 3.1 ± 2.1** 36.9 ± 2.6 6.6 ± 0.2** 9.3 ± 1.8**
Hill slope 1 1 1 1 1
(n) (3) (2) (3) (2) (3)
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signaling. Moreover, depletion of membrane cholesterol has
more pronounced effects than cholesterol supplementation
on the efficacy of the agonist carbachol. This observation is
in line with our preceding finding of reduced efficacy of
carbachol-stimulated IPs accumulation in CHO-M1 cells
induced by membrane cholesterol manipulation [28].
With respect to ligand binding, the major outcome of
cholesterol depletion common for both cell lines was an
increase in the density of antagonist binding sites in both cell
lines that was accompanied with a small decrease in affinity
(by 71 %) only in CHO-M1 cells at the highest level of
cholesterol reduction. Conversely, cholesterol supplemen-
tation decreased the density of binding sites at both cell lines
only after the highest cholesterol supplementation with a
small decrease in affinity (by 62 %) only in CHO-M3 cells.
We observed similar effects of cholesterol depletion in
CHO-M2 cells [28] so that we assume that changes in
receptor densities after membrane cholesterol manipulations
are due to modifications in the accessibility of receptors to
the antagonist ligand consequent to alterations of membrane
physicochemical properties [11]. Unlike in CHO-M2 cells
and membranes, we found no essential membrane choles-
terol concentration-dependent changes in parameters of
agonist binding in CHO-M1 and CHO-M3 cell lines or
membranes prepared from treated cells. The differential
pattern of changes in ligand binding characteristics among
these three cell lines indicate that they are not an experi-
mental artifact arising out of the treatment.
(a) (b)
Fig. 3 Influence of membrane cholesterol concentration on carba-
chol-evoked cAMP synthesis in CHO-M1 and CHO-M3 cells. Cells
were labeled with 3H-adenine and then pretreated with MBCD or
cholesterol-saturated MBCDto decrease or increase membrane cho-
lesterol content, respectively. Increase in labeled cAMP synthesis in
CHO-M1 (a) and CHO-M3 (b) cells expressed in percent of
incorporated radioactivity is plotted against carbachol concentration
(abscissa; log M). The cells were treated with 5 mM MBCD (open
squares) to reduce membrane cholesterol or with 2 mM Ch-MBCD
(closed squares) to increase membrane cholesterol as described in
‘‘Methods’’. Points are mean ± SEM of 3 experiments in triplicates.
Open circles, control (KHB treated) cells. Parameters of fits (three
parameter sigmoidal concentration–response equation for both cell
lines) are shown in Table 4
Table 4 Influence of changes in cholesterol concentration on car-






Basal synthesis (%) 0.97 ± 0.13** 0.45 ± 0.02 0.40 ± 0.02
Emax (%) 6.13 ± 0.32** 2.09 ± 0.08 0.94 ± 0.07*
EC50 (lM) 143 ± 23 146 ± 22 170 ± 29
M3 cells
Basal synthesis (%) 0.98 ± 0.12* 0.59 ± 0.09 0.56 ± 0.04
Emax (%) 2.95 ± 0.32** 1.01 ± 0.03 0.25 ± 0.07*
EC50 (lM) 124 ± 4 147 ± 27 110 ± 93
Data are expressed as mean ± SEM of three independent experiments
in triplicates. Values for cAMP synthesis are expressed in percent of
loaded radioactivity that did not differ among treatments. Pooled
value of incorporated radioactivity was 216,550 ± 10,542 dpm/well
(n = 18). * p\ 0.05; ** p\ 0.01; significantly different from con-
trols (middle column) by Anova followed by Dunnett’s multiple
comparison test
2074 Neurochem Res (2015) 40:2068–2077
123
Experiments aimed at determination of the effects of
manipulation of membrane cholesterol on various elements
of signal transduction yielded interesting results. There was
no difference in total binding of GTP-c35S (denoting
G-protein concentration) between CHO-M1 and CHO-M3
(and also CHO-M2; not shown) membranes. Cholesterol
depletion slightly augmented (by 18 %) while cholesterol
supplementation slightly attenuated (by 8 %) total GTP-
c35S binding. We suppose that similar to antagonist bind-
ing, cholesterol concentration manipulations unmask or
mask some GTP binding sites in membranes. In support of
this view, western blot analysis of lysed membranes after
cholesterol modifying treatment did not reveal any changes
in the concentration of the major G-protein subclasses a-
subunits indicating that the total protein concentration of a-
subunits was not changed by the treatment [28]. Note-
worthy, however, manipulation of cholesterol content may
influence the stoichiomentry of GTP interaction with G
proteins. While the influence of cholesterol modifications
on resting (in the absence of agonist) binding was basically
similar in both CHO-M1 and CHO-M3 membranes, car-
bachol-stimulated GTP-c35S binding markedly differed
between them. Agonist-stimulated GTP-c35S binding in
control CHO-M1 membranes was best fitted by a sigmoidal
curve with Hill slope less than unity that was not at all
influenced by changes in membrane cholesterol concen-
tration. In contrast, carbachol-stimulated GTP-c35S binding
in CHO-M3 membranes followed a three-parameter sig-
moidal concentration–response curve. In addition, unlike in
CHO-M1 cells, both cholesterol depletion and supple-
mentation concentration-dependently reduced the maximal
effect of carbachol but increased its potency. Together with
the lack of effect on agonist binding these results provide
evidence for alteration of M3 receptor-mediated Gs
G-protein signaling also upstream of activated G-protein/
effector protein interaction.
Effects of changes in membrane cholesterol concentra-
tion exhibited different patterns on agonist-induced stimu-
lation of the nonpreferential Gs G-protein signaling pathway
than the pattern of overall G-protein activation or stimula-
tion of the preferential phosphatidylinositol hydrolysis
pathway. In both intact CHO-M1 and CHO-M3 cells, cho-
lesterol depletion increased while cholesterol supplemen-
tation decreased carbachol-evoked cAMP synthesis. The
sense of changes in muscarinic receptor stimulation-evoked
metabolism of second messengers that result from altera-
tions in membrane cholesterol concentration is basically the
same in both cell lines. However, mechanisms of these
changes differ in CHO-M1 and CHO-M3 cells. Results of
binding experiments demonstrate that signal transmission
across the membrane via the M1 receptor is not influenced
by membrane cholesterol concentration. On the other hand,
changes in membrane cholesterol concentration influence
both agonist binding and G-protein activation in CHO-M3
cells. Together these data indicate that alterations in M1
receptor signaling as a results of changes in membrane
cholesterol concentration are due to events downstream of
receptor/G-protein activation while impact on M3 receptor
signaling involves both components.
A role of cholesterol in the pathogenesis of Alzheimer’s
disease remains a matter of controversy, in spite of the
involvement of several research groups in such studies.
Thus, considerable experimental evidence supporting both
the beneficial and detrimental role of both increased and
reduced cell cholesterol exists [25, 32, 36]. Most of
experimental work has focused on mutual interactions of
membrane cholesterol and constitutive cleavage of amyloid
precursor protein and a role of b-amyloid in lipid metab-
olism [10]. It has been demonstrated that an increase in
membrane cholesterol facilitates production of noxious b-
amyloid fragments while reduction in membrane choles-
terol has the opposite effect [7, 8, 34, 35, 38]. On the other
hand, a decrease in membrane cholesterol concentration
was detected in a subgroup of post mortem Alzheimer´s
brains with reduced activity of the amyloid peptites
degrading protease plasmin [23]. In other experiments, a
small decrease in membrane cholesterol resulted in an
increase in amyloid-b production while inhibition of
amyloid-b production required a large decrease in choles-
terol content [1]. Our results indicate that a relatively small
drop in membrane cholesterol already results in highly
significant attenuation in agonist-evoked Gq/11 G-protein-
mediated M1 receptor signaling (Fig. 1: decrease by 35 %,
p\ 0.0001 by Anova and Dunnett’s test; decrease by
17 %, p\ 0.027 by two-tailed t-test) that may attenuate a-
secretase activity.
In summary, we demonstrate that changes in membrane
cholesterol concentration markedly influence M1 and M3
muscarinic receptor-mediated signaling to the cell interior.
Our data illustrate that changes in membrane cholesterol
concentration have essentially no influence on M1 receptor/
G-proteins interactions, suggesting that changes in signaling
take place distal to this step. With regard to the preferential
Gq/11 G-protein signaling pathway both increase and
decrease in membrane cholesterol concentration results in
concentration-dependent inhibition of accumulation of ino-
sitol phosphates. These effects are not due to a loss of
phosphatidylinositol-specific phospholipaseC because basal
values (in the absence of agonist) are either not changed
(high cholesterol) or increased (low cholesterol). Non-pref-
erential agonist-stimulated Gs G-protein-mediated signaling
differs from the inositol phosphates response. The decrease
in membrane cholesterol concentration increases the cAMP
response while increase in membrane cholesterol concen-
tration inhibits the response. Taken together these results
point to the activated G-protein/effector protein interaction
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as the main site of action in the observed alterations of M1
receptor-mediated stimulation of second messenger path-
ways. These changes most likely depend on physicochemi-
cal properties of the membrane and changes in receptor
localization and mobility within the membrane. On the other
hand, alterations in agonist-stimulated GTP-c35S binding in
CHO-M3membranes indicate that in case of theM3 receptor
additional modification of liganded receptor/G-protein
interaction may also play a role.
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